Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference
<!-- Name:DistributionId Value:8807537 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Cabaletta Bio
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of…
<!-- Name:DistributionId Value:8799423 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy…
– Company has obtained exclusive worldwide license for a fully human CD19 binder with clinical tolerability data that support potential clinical development in autoimmune diseases –…
Cabaletta Bio to Present DSG3-CAART Clinical Data and MuSK-CAART Preclinical Data at…
PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell…
U.S. Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for…
– Fast Track Designation granted to improve activities of daily living and muscle strength in patients with MuSK antibody-positive myasthenia gravis – PHILADELPHIA, March 01, 2022 (GLOBE…
Cabaletta Bio to Present at the H.C. Wainwright BioConnect Conference
PHILADELPHIA, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell…
Cabaletta Bio to Participate in Upcoming Investor Conferences in November
PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell…